You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Previously Treated

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Solid Tumor, Adult
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 13, 2023

Colorectal Cancer Trial (ME-344, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 20, 2023

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

Not yet recruiting
  • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
  • Ivosidenib 500mg
  • Placebo
  • (no location specified)
Nov 7, 2023

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Participants Previously Treated With Century Therapeutics

Not yet recruiting
  • Hematological Malignancy
  • Solid Tumor Malignancy
  • No Intervention
  • (no location specified)
Mar 3, 2023

Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

Not yet recruiting
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • (no location specified)
Oct 10, 2023

Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Enfortumab vedotin
  • Kansas City, Kansas
    University of Kansas Cancer Center
Jun 23, 2023

Peri-implant Mucositis, Peri-Implantitis Trial in Pittsburgh (Induction of experimental peri-implant mucositis, Resolution of

Recruiting
  • Peri-implant Mucositis
  • Peri-Implantitis
  • Induction of experimental peri-implant mucositis
  • Resolution of experimental peri-implant mucositis
  • Pittsburgh, Pennsylvania
    University of Pittsburgh School of Dental Medicine
Sep 25, 2023

Kaposi Sarcoma, Classic Kaposi Sarcoma, Refractory Kaposi Sarcoma Trial (Pembrolizumab + Lenvatinib)

Not yet recruiting
  • Kaposi Sarcoma
  • +2 more
  • Pembrolizumab + Lenvatinib
  • (no location specified)
Apr 27, 2023

NSCLC Trial (SGN-B6A, docetaxel)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 21, 2023

NSCLC Trial in Changsha (BEBT-109)

Completed
  • NSCLC
  • Changsha, Hunan, China
    Hunan Cancer hospital
Aug 20, 2023

Colorectal Cancer Metastatic Trial (EO2401)

Not yet recruiting
  • Colorectal Cancer Metastatic
  • (no location specified)
Feb 2, 2023

Soft Tissue Sarcoma Trial (ADI PEG20, Placebo)

Not yet recruiting
  • Soft Tissue Sarcoma
  • ADI PEG20
  • Placebo
  • (no location specified)
Jan 31, 2023

Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Gastric Cancer Metastatic to Liver
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 6, 2023

Diabetes, Lipodystrophy, Hyperlipidemia Trial run by the NIDDK (Metreleptin)

Active, not recruiting
  • Diabetes
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 21, 2023

Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Mar 23, 2023

Primary Immune Thrombocytopenia (ITP) Trial (Ianalumab)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • Ianalumab
  • (no location specified)
Jun 5, 2023

Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

Recruiting
  • Advanced Biliary Tract Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 22, 2023

Nasopharyngeal Carcinoma Trial in Beijing (Donafenib)

Recruiting
  • Nasopharyngeal Carcinoma
  • Beijing, Beijing, China
    Cancer Hospital of Medical College
Nov 28, 2022

Lipodystrophy, Diabetes, Hyperlipidemia Trial run by the NIDDK (Metreleptin)

Recruiting
  • Lipodystrophy
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases Trial (Renal Autologous Cell Therapy (REACT))

Not yet recruiting
  • Diabetic Kidney Disease
  • +2 more
  • Renal Autologous Cell Therapy (REACT)
  • (no location specified)
Jan 11, 2023

Long Term Efficacy and Safety Trial (Imlifidase administered in the 20-HMedIdeS-19 (PAES) study, Best available treatment

Not yet recruiting
  • Long Term Efficacy and Safety
  • Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
  • Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
  • (no location specified)
Jun 30, 2023

NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

Not yet recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Apatinib + Fluzoparib
  • Apatinib + Fluzoparib + Adebrelimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 27, 2023

Participants Previously Treated With EB-101 for Treatment of

Enrolling by invitation
  • RDEB
  • EB-101
  • Redwood City, California
  • +1 more
Feb 1, 2023

Solid Tumor Trial in Barcelona, Madrid (OMX-0407)

Recruiting
  • Solid Tumor
  • Barcelona, Spain
  • +1 more
Apr 28, 2023